Arch Point Investors Iovance Biotherapeutics, Inc. Transaction History

Arch Point Investors

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$9.53 - $13.11 $14,294 - $19,665	-1,500 Reduced 1.6%	92,500 $886,000
Q2 2022 Aug 12, 2022	SELL	$6.38 - $18.33 $3,190 - $9,165	-500 Reduced 0.53%	94,000 $1.04 Million
Q3 2021 Nov 12, 2021	SELL	$20.35 - $26.63 $59,910 - $78,398	-2,944 Reduced 3.02%	94,500 $2.33 Million
Q2 2021 Aug 13, 2021	BUY	$16.33 - $33.07 $412,757 - $835,877	25,276 Added 35.02%	97,444 $2.54 Million
Q1 2021 May 13, 2021	BUY	$28.67 - $52.59 $86,010 - $157,770	3,000 Added 4.34%	72,168 $2.29 Million
Q4 2020 Feb 12, 2021	BUY	$28.04 - $50.26 $1.61 Million - $2.89 Million	57,418 Added 488.66%	69,168 $3.21 Million
Q3 2020 Nov 13, 2020	BUY	$27.75 - $36.3 $326,062 - $426,524	11,750 New	11,750 $387,000
Q1 2019 May 10, 2019	SELL	$8.41 - $11.26 $42,050 - $56,300	-5,000 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$7.51 - $11.93 $37,550 - $59,650	5,000 New	5,000 $44,000

314

241M

3.77M

1.7M

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $1.35B
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

Get notified when there are updates to the investment portfolio of Arch Point Investors, based on Form 13F filings with the SEC.

Stay updated on Arch Point Investors with notifications on news.